Initial Statement of Beneficial Ownership (3)
03 Janvier 2023 - 3:48PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Myers Michael |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2023
|
3. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [QNRX]
|
(Last)
(First)
(Middle)
AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, 132 MENACHEM BEGIN BLVD |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Executive Officer / |
(Street)
TEL AVIV, L3 6701101
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Ordinary Shares | 561480000 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Share Option (right to buy) | 4/12/2023 (2) | 4/12/2032 | Ordinary Shares | 428571600 (3) | $0.0035 (3) | D | |
Explanation of Responses: |
(1) | Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents five thousand (5,000) ordinary shares of the Issuer. |
(2) | The option vests in four equal annual installments beginning on April 12, 2023. |
(3) | The number of securities underlying the option and the exercise price are listed in terms of ordinary shares, with five thousand (5,000) ordinary shares of the Issuer
represented by one (1) ADS, which evidences the grant of an option to buy 85,714.32 ADSs at the exercise price of $17.50 per ADS. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Myers Michael AZRIELI CENTER, ROUND TOWER, 30TH FLOOR 132 MENACHEM BEGIN BLVD TEL AVIV, L3 6701101 | X |
| Chief Executive Officer |
|
Signatures
|
/s/ Michael Myers | | 1/1/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Cellect Biotechnology (NASDAQ:APOP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cellect Biotechnology (NASDAQ:APOP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Cellect Biotechnology Ltd (NASDAQ): 0 recent articles
Plus d'articles sur Quoin Pharmaceuticals, Ltd.